Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 202 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Influenza Type A Clear all

Conditions: Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: bortezomib, fludarabine phosphate, melphalan, total marrow irradiation, tacrolimus, sirolimus, peripheral blood stem cell transplantation, laboratory biomarker analysis; Drug · Other · Radiation + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: Duarte, California

Conditions: Influenza
Interventions: TCAD, Zanamivir or Oseltamivir, Open label treatment with TCAD; Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 1 Year and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Decitabine plus Fludarabine and Busulfan; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 45 Years to 80 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Influenza
Interventions: Influenza A/H5N1 Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 452 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 3
States / cities: Torrance, California • Baltimore, Maryland • Rochester, New York

Conditions: Influenza, Human
Interventions: A/swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca (H2N3 MO 2006/AA ca), A/chicken/Hong Kong/G9/97 (H9N2) x A/Ann Arbor/6/60 ca (H9N2 G9/AA ca), 2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®), Vaccine placebo (Leibovitz-15 [L-15]), Vaccine placebo (FluMist®); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 42 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Rochester, New York

Conditions: COVID-19, Influenza A, Influenza Type B, RSV Infection
Interventions: LumiraDx SARS-CoV-2 & Flu A/B test, LumiraDx SARS-CoV-2 & RSV test; Diagnostic Test
Lead sponsor: LumiraDx UK Limited; Industry
Eligibility: Not listed
Enrollment: 589 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 8
States / cities: Cullman, Alabama • Encinitas, California • Miami, Florida + 5 more

Conditions: Influenza, Virus Diseases
Interventions: H6N1 Teal HK 97/AA ca recombinant vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza
Interventions: Inactivated H1N1 Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 406 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Baltimore, Maryland • Durham, North Carolina • Nashville, Tennessee

Conditions: Influenza A H3N2, Influenza A H1N1
Interventions: FLU-IGIV, Placebo for FLU-IGIV; Biological · Other
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 42
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 34 more

Conditions: Influenza
Interventions: VXA-A1.1, Fluzone®, Placebo Tablets, Saline Solution for Placebo IM Injection; Biological · Other
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 179 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Costa Mesa, California

Conditions: Determine Minimally to Moderately Infective Dose (MMID) of Influenza A H3N2
Interventions: Live recombinantly derived A/Bethesda/MM1/H3N2 virus; Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Subjects Possibly Exposed to COVID-19
Interventions: Not listed
Lead sponsor: Biocerna LLC; Industry
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Fulton, Maryland

Conditions: Influenza
Interventions: Influenza A/Vietnam/1203/2004 (H5N1; sanofi pasteur); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza A Subtype H5N1 Infection
Interventions: Seasonal Influenza Vaccine; Biological
Lead sponsor: Emory University; Other
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Influenza A
Interventions: Low dose of VIS410, High dose of VIS410, Placebo; Drug
Lead sponsor: Visterra, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 21
States / cities: Tucson, Arizona • Stanford, California • St. Petersburg, Florida + 18 more

Conditions: Seasonal Influenza Preventative Vaccine Pharmacodynamics
Interventions: VXA-A1.1 H1 Tablet Vaccine (small), VXA-A1.1 H1 Tablet Vaccine (large); Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Influenza
Interventions: CR6261 2 mg/kg, CR6261 5 mg/kg, CR6261 15 mg/kg, CR6261 30 mg/kg, CR6261 50 mg/kg, Placebo; Biological
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Influenza, Human
Interventions: zanamivir aqueous solution; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 33 more

Conditions: Influenza A Virus Infection
Interventions: Collection of Anti-Influenza A Immune Plasma; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 59 Years · Male only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2019
U.S. locations: 2
States / cities: San Diego, California • Bethesda, Maryland

Conditions: Haemophilus Influenzae Type B, Carrier State
Interventions: Hib conjugate vaccine (HbOC, Wyeth Vaccines); Biological
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 0 Years and older
Enrollment: 3,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Anchorage, Alaska

Conditions: Influenza, Human
Interventions: Flu Symptoms; Device
Lead sponsor: Sekisui Diagnostics, LLC; Industry
Eligibility: 3 Months and older
Enrollment: 677 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Winston-Salem, North Carolina • Charleston, South Carolina • New Braunfels, Texas

Conditions: Influenza A, Influenza B, Respiratory Syncytial Virus (RSV)
Interventions: Not listed
Lead sponsor: IQuum, Inc.; Industry
Eligibility: Not listed
Enrollment: 1,642 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Delray Beach, Florida • Savannah, Georgia • Indianapolis, Indiana + 5 more

Conditions: Influenza A Virus Infection
Interventions: H2N3 MO 2003/AA ca Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 42 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza
Interventions: Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 10 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 3
States / cities: Torrance, California • Baltimore, Maryland • St Louis, Missouri

Search by objective public record fields.

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients

PRO#0118: Decitabine Plus Mini Flu-Bu

A/H5N1in Adult - Aventis

Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines

Performance Evaluation of LumiraDx SARS-CoV-2, Flu A/B, and RSV Tests for COVID-19 Assessment

Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine

Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations

Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A

A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine

Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers

Assessment of Self-Collected Sample Compared to Clinician Collected Sample in COVID-19 and Influenza Program

Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine

Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response

Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A

Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults

Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus

Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital

Blood and Plasma Collection For Use in Future Clinical Trials

Study to Eliminate Hib Carriage in Rural Alaska Native Villages

Clinical Performance Study of the Ultra Influenza A&B Test Using Nasal Swabs for Identifying Subjects Who Are Infected With the Influenza Virus Strain Type A or Type B

Detection of Influenza A, Influenza B, and RSV Using the Liat™ Assays on the Liat™ Analyzer

Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza

Open-Label Study of H5 Vaccine in Participants of Protocol 04-077